- Home
- SAGE vs HUMA Comparison
SAGE vs HUMA Comparison
Compare SAGE & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAGE
- HUMA
- Stock Information
- Founded
- SAGE 2010
- HUMA 2004
- Country
- SAGE United States
- HUMA United States
- Employees
- SAGE N/A
- HUMA N/A
- Industry
- SAGE Biotechnology: Pharmaceutical Preparations
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- SAGE Health Care
- HUMA Health Care
- Exchange
- SAGE Nasdaq
- HUMA Nasdaq
- Market Cap
- SAGE 444.1M
- HUMA 503.1M
- IPO Year
- SAGE 2014
- HUMA N/A
- Fundamental
- Price
- SAGE $7.31
- HUMA $3.54
- Analyst Decision
- SAGE Hold
- HUMA Strong Buy
- Analyst Count
- SAGE 20
- HUMA 7
- Target Price
- SAGE $10.67
- HUMA $13.43
- AVG Volume (30 Days)
- SAGE 1.8M
- HUMA 1.6M
- Earning Date
- SAGE 02-11-2025
- HUMA 03-21-2025
- Dividend Yield
- SAGE N/A
- HUMA N/A
- EPS Growth
- SAGE N/A
- HUMA N/A
- EPS
- SAGE N/A
- HUMA N/A
- Revenue
- SAGE $41,243,000.00
- HUMA N/A
- Revenue This Year
- SAGE $123.13
- HUMA N/A
- Revenue Next Year
- SAGE $69.65
- HUMA $4,344.68
- P/E Ratio
- SAGE N/A
- HUMA N/A
- Revenue Growth
- SAGE N/A
- HUMA N/A
- 52 Week Low
- SAGE $4.62
- HUMA $2.81
- 52 Week High
- SAGE $23.22
- HUMA $9.97
- Technical
- Relative Strength Index (RSI)
- SAGE 60.55
- HUMA 29.77
- Support Level
- SAGE $7.00
- HUMA $3.70
- Resistance Level
- SAGE $7.26
- HUMA $4.14
- Average True Range (ATR)
- SAGE 0.19
- HUMA 0.22
- MACD
- SAGE -0.06
- HUMA -0.06
- Stochastic Oscillator
- SAGE 57.14
- HUMA 0.00
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.